1. Home
  2. HXHX vs CMMB Comparison

HXHX vs CMMB Comparison

Compare HXHX & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HXHX

Haoxin Holdings Limited Class A Ordinary Shares

HOLD

Current Price

$0.51

Market Cap

12.0M

Sector

Industrials

ML Signal

HOLD

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

HOLD

Current Price

$1.69

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXHX
CMMB
Founded
2003
2004
Country
China
Israel
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.0M
13.8M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
HXHX
CMMB
Price
$0.51
$1.69
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$26.50
AVG Volume (30 Days)
17.4M
85.1K
Earning Date
02-18-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
1.80
N/A
EPS
0.30
N/A
Revenue
$34,088,144.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.69
N/A
Revenue Growth
32.57
N/A
52 Week Low
$0.33
$1.60
52 Week High
$6.29
$8.80

Technical Indicators

Market Signals
Indicator
HXHX
CMMB
Relative Strength Index (RSI) 43.88 33.76
Support Level $0.47 $1.70
Resistance Level $0.62 $1.85
Average True Range (ATR) 0.10 0.15
MACD -0.01 0.02
Stochastic Oscillator 5.73 22.50

Price Performance

Historical Comparison
HXHX
CMMB

About HXHX Haoxin Holdings Limited Class A Ordinary Shares

Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: